RXRX · Company research
Recursion Pharmaceuticals, Inc. (RXRX): Valuation Analysis
Available valuation snapshots and ratios; unavailable metrics remain blank.
RESEARCH CONTEXT
Understand the numbers
Available valuation snapshots and ratios; unavailable metrics remain blank. Use period, currency, units and source fields when interpreting values.
1records availableHealthcare
Valuation Analysis data
Database-backed records only
| valuation date | price | market cap | enterprise value | pe | forward pe | peg | price sales | price book | price fcf |
|---|---|---|---|---|---|---|---|---|---|
| Oct 8, 2026 | 4.63 | $2,314,683,683.08 | 1769000683.08 | — | — | — | 148.2725358375167928 | — | — |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.